Jennison Associates
ITCI

Jennison Associates’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Jennison Associates’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-241,800
Closed -$3.69M – 836
2016
Q3 		$3.69M Buy
+241,800
New +$9.78M ﹤0.01% 519

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jennison Associates's ITCI Position: Q2 2024 in Review

Jennison Associates sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2024, closing a stake of 9,212 shares — an estimated $637K sold.

Jennison Associates first reported a position in ITCI in Q3 2015 and held it in 13 quarters. The position peaked at $67.7M in Q4 2015. 375 funds tracked by Wall St. Rank hold ITCI as of Q2 2024.

  • Jennison Associates reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2024 after selling out during the quarter.
  • Jennison Associates sold 9,212 Intra-Cellular Therapies Inc. shares in Q2 2024, an estimated $637K.
  • Jennison Associates first reported a position in Intra-Cellular Therapies Inc. in Q3 2015 and held it in 13 quarters.
  • Jennison Associates's Intra-Cellular Therapies Inc. position peaked at $67.7M in Q4 2015.
  • 375 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2024.

Based on Jennison Associates's 13F filing for Q2 2024, filed 5 Aug 2024.